(Q53223082)

12 May 2018

review article

1 reference

title

Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? (English)

1 reference

12 May 2018

author name string

Benzi G

series ordinal

1

1 reference

12 May 2018

Moretti A

series ordinal

2

1 reference

12 May 2018

language of work or name

English

0 references

publication date

1 April 1998

1 reference

12 May 2018

European Journal of Pharmacology

published in

1 reference

12 May 2018

volume

346

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

page(s)

1-13

1 reference

12 May 2018

The search for disease-modifying treatment for Alzheimer's disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

A neurochemical approach for studying response to acetylcholine in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Secreted acetylcholinesterase: non-classical aspects of a classical enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

The cholinergic hypothesis of geriatric memory dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Chemical pathology of this organic dementias. II. Quantitative estimation of cellular changes in post-mortem brains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Alpha 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Neurotransmitter receptor/G-protein mediated signal transduction in Alzheimer's disease brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Cholinergic and serotonergic stimulation of phosphoinositide hydrolysis is decreased in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Selective loss of central cholinergic neurons in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

The role of interactions between the cholinergic system and other neuromodulatory systems in learing and memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Tacrine in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Regulated secretion of beta-amyloid precursor protein in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Rodent models of Alzheimer's disease: rat A beta infusion approaches to amyloid deposits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Tacrine: A pharmacological review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Diminished [3H]inositol(1,4,5)P3 but not [3H]inositol(1,3,4,5)P4 binding in Alzheimer's disease brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Cholinesterases and the Pathology of Alzheimer Disease

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Cholinergic receptors in human brain: effects of aging and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Differential effects of amyloid peptides beta-(1-40) and beta-(25-35) injections into the rat nucleus basalis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Ultrastructural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer disease patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Cytosol protein kinase C downregulation in fibroblasts from Alzheimer's disease patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Phosphoinositide hydrolysis, G alpha q, phospholipase C, and protein kinase C in post mortem human brain: effects of post mortem interval, subject age, and Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Decreased inositol (1,4,5)-trisphosphate receptor levels in Alzheimer's disease cerebral cortex: selectivity of changes and possible correlation to pathological severity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Cholinergic activation of phosphoinositide signaling is impaired in Alzheimer's disease brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Regional Alterations in M., Muscarinic Receptor-G Protein Coupling in Alzheimerʼs Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Protein kinase C alteration is an early biochemical marker in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Abnormalities of acetylcholinesterase in Alzheimer's disease with special reference to effect of acetylcholinesterase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Metrifonate effects on acetylcholine and biogenic amines in rat cortex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Cholinesterase inhibitors increase secretion of APPs in rat brain cortex.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Correlations between neuropathological and neurochemical changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

From the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Tetrahydroaminoacridine induces opposite changes in muscarinic and nicotinic receptors in rat brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Role of neurotransmission in the regulation of amyloid beta-protein precursor processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Metrifonate and tacrine: a comparative study on their effect on acetylcholine dynamics in mouse brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Preferential inhibition of acetylcholinesterase molecular forms in rat brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Normal sequences of muscarinic acetylcholine receptors (m1 and m2) in patients with Alzheimer's disease and vascular dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Neurochemical studies of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Acetylcholine and brain aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Memory disorders: novel treatments, clinical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

The cholinergic hypothesis--ten years on.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Galanthamine in Alzheimer's disease : a new alternative to tacrine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Cognitive functions of cortical acetylcholine: toward a unifying hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Soluble and membrane-bound forms of brain acetylcholinesterase in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Normal and abnormal biology of the beta-amyloid precursor protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Neuropeptide changes in dementia: pathogenetic implications and diagnostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Effects of Alzheimer's disease-related beta amyloid protein fragments on enzymes metabolizing phosphoinositides in brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Receptor-mediated activation of G proteins is reduced in postmortem brains from Alzheimer's disease patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Attenuated protein kinase C activity and translocation in Alzheimer's disease brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Coupling of muscarinic receptors to GTP proteins in postmortem human brain--alterations in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease. Effect on cognition, functioning in daily life, behavioural disturbances and burden experienced by the carers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Protease inhibitors and indoleamines selectively inhibit cholinesterases in the histopathologic structures of Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Mechanisms of neuronal degeneration in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Tetrameric (G4) acetylcholinesterase: structure, localization, and physiological regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900093-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(98)00093-4

1 reference

12 May 2018

PubMed ID

9617746

1 reference

12 May 2018